Risks of Continuing IV Iron in CKD Patients with Ferritin >1000 ng/mL

Guideline-Based Upper Limits for Iron Therapy

• The National Kidney Foundation recommends withholding IV iron when ferritin exceeds 800 ng/mL or transferrin saturation (TSAT) exceeds 50%, as most patients will have achieved target hemoglobin levels at these thresholds and are unlikely to respond with further increases 1
• The American College of Cardiology is not mentioned in this context, however, the NKF-K/DOQI guidelines state that patients are unlikely to respond with further hemoglobin increases or ESA dose reductions when ferritin reaches 800 ng/mL, making continued administration at levels >1000 ng/mL clinically unjustified 2
• After withholding iron for up to 3 months, recheck iron parameters before resuming therapy at a reduced dose (one-third to one-half of the previous weekly dose) once ferritin falls below 800 ng/mL and TSAT below 50% 1

Limited Evidence for Safety at Ferritin >1000 ng/mL

• The DRIVE study demonstrated hemoglobin increases with IV iron in patients with ferritin levels between 500-1200 ng/mL and TSAT <25%, but the study was not adequately powered to assess safety outcomes such as infections, cardiovascular events, or mortality 3

Theoretical and Observed Risks

• The long-term safety of maintaining ferritin >1000 ng/mL remains untested in large randomized trials, and while organ damage from hemochromatosis typically occurs at dramatically higher ferritin levels, an estimated 20+ grams of excess iron is necessary to cause organ damage 3
• Anemia (hemoglobin <9 g/dL), rather than elevated ferritin, is the primary risk factor for bacteremia in hemodialysis patients, and polymorphonuclear granulocyte dysfunction observed in iron-overloaded dialysis patients has been shown to normalize with either deferoxamine or erythropoietin therapy, even with ferritin levels remaining >1000 ng/mL 4
• Since ferritin is an acute phase reactant, infection itself can elevate ferritin into ranges suggesting iron overload, making the association between high ferritin and infection potentially bidirectional rather than causal 4

Practical Management Algorithm

• Immediately withhold all IV iron administration when ferritin is >1000 ng/mL, and continue monitoring ferritin and TSAT every 3 months during the withholding period 1, 2
• Wait at least 4-8 weeks after the last IV iron dose before rechecking iron parameters, as ferritin becomes falsely elevated immediately after IV iron and remains unreliable during this window 5, 6
• Reassess after 2-3 months of withholding iron: In hemodialysis patients, ferritin levels typically decline due to repetitive dialyzer blood losses, with studies showing decreases from 754-836 ng/mL to 183-477 ng/mL within 3-4 months of withholding IV iron 4
• Resume IV iron only when ferritin falls below 800 ng/mL and TSAT below 50%, using a reduced weekly dose (one-third to one-half of previous dose) 1
• Even with ferritin >1000 ng/mL, if TSAT remains <25% and hemoglobin is suboptimal despite adequate ESA dosing, the patient may have functional iron deficiency in the setting of inflammation, but the safety of continuing IV iron in this scenario remains unproven 3

Critical Pitfalls to Avoid

• Do not check ferritin within 4 weeks of IV iron administration, as it yields falsely elevated readings that do not reflect true iron stores and may lead to inappropriate continuation of therapy 5, 6
• Do not assume that higher ferritin levels always indicate adequate iron stores in the presence of inflammation, as ferritin is an acute phase reactant; however, this does not justify continuing IV iron at ferritin >1000 ng/mL given the lack of safety data 4
• Do not continue IV iron simply because hemoglobin remains below target when ferritin exceeds 800-1000 ng/mL, as the patient is unlikely to respond with further increases and may be experiencing ESA hyporesponsiveness from other causes 2, 1

Guidelines for Reducing or Discontinuing Iron Polymaltose in Renal Patients

Thresholds for Discontinuation

Monitoring Frequency and Target Parameters

Dose Adjustment and Resumption Criteria

Lack of Hemoglobin Response

Pharmacokinetic Considerations for Iron Polymaltose

Risks of Iron Overload

Evidence quality: The thresholds and monitoring recommendations are derived from the KDIGO 2012 guideline (high‑quality evidence) 7; pharmacokinetic and MRI safety data are based on pharmacological and imaging studies published in Drugs (2016) [9][10]11; the response‑failure recommendation originates from a clinical consensus statement (JNCCN 2012) 8.